A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AFTER SOLID ORGAN TRANSPLANTATION12

Autor: DUNN, DAVID L., GILLINGHAM, KRISTEN J., KRAMER, MARIE A., SCHMIDT, WALTER J., ERICE, ALEJO, BALFOUR, HENRY H., GORES, PAUL F., GRUESSNER, RAINER W. G., MATAS, ARTHUR J., PAYNE, WILLIAM D., SUTHERLAND, DAVID E. R., NAJARIAN, JOHN S.
Zdroj: Transplantation; March 1994, Vol. 57 Issue: 6 p876-883, 8p
Abstrakt: Cytomegalovirus disease occurs frequently after solid organ transplantation and has been associated with decreased patient and allograft survival. We hypothesized that CMV transmission or reactivation begins immediately or soon after transplantation, and that a short-duration ganciclovir (GCV)-based regimen would obviate the need for long-term antiviral agent administration, perhaps serving to interdict CMV infection and disease as well as, or perhaps even more effectively than, a more prolonged, oral acyclovir (ACV)-based form of prophylaxis. A total of 311 patients were stratified according to allograft type, age, and presence or absence or diabetes mellitus, and were then randomized to receive either long-duration ACV prophylaxis (800 mg orally or 400 mg i.v. q.i.d. for
Databáze: Supplemental Index